SEC Form 4 · accession 0001209191-17-066833
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John F Crowley
Officer — Chairman & CEO · Director
Period of report
Dec 20, 2017
Accepted (ET)
Dec 21, 2017 · 5:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Dec 20, 2017 | M | 65,075 | $13.5064 | A | 393,076 | D | |
| Common StockF3 | Dec 20, 2017 | S | 65,075 | $13.5064 | D | 328,001 | D | |
| Common StockF4 | Dec 21, 2017 | M | 506 | $13.509 | A | 358,507 | D | |
| Common StockF5 | Dec 21, 2017 | S | 506 | $13.509 | D | 328,001 | D | |
| Common Stock | holding | — | — | — | 64,895 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy) | $10.21 | Dec 20, 2017 | M | 65,075 | D | Feb 5, 2009 | Feb 5, 2018 | Common Stock | 65,075 | 506 | D |
| Stock Options (right to buy) | $10.21 | Dec 21, 2017 | M | 506 | D | Feb 5, 2009 | Feb 5, 2018 | Common Stock | 506 | 0 | D |
Explanation of responses
- F1The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.
- F2This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.50 to $13.54. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F3This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.50 to $13.54. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.50 to $13.52. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F5This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.50 to $13.52. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Remarks
The options exercised were issued to Mr. Crowley in February 2008 and these options would have expired in February 2018.